A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity-Reference-Cited by-同舟云学术

A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity

Published:2019-04-24 Issue:489 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Karnell Jodi L.¹^ORCID,Albulescu Marius²,Drabic Stacey³^ORCID,Wang Liangwei¹,Moate Rachel⁴,Baca Manuel³,Oganesyan Vaheh³^ORCID,Gunsior Michele¹^ORCID,Thisted Thomas³,Yan Li¹,Li Jing⁵,Xiong Ximing³,Eck Steven C.³^ORCID,de los Reyes Melissa³^ORCID,Yusuf Isharat³,Streicher Katie³^ORCID,Müller-Ladner Ulf⁶,Howe David⁴^ORCID,Ettinger Rachel¹,Herbst Ronald³^ORCID,Drappa Jörn¹^ORCID

Affiliation:

1. Viela Bio, Gaithersburg, MD 20878, USA.

2. AstraZeneca, Cambridge CB4 OWG, UK.

3. MedImmune, Gaithersburg, MD 20878, USA.

4. MedImmune, Granta Park, Cambridge CB21 6GH, UK.

5. MedImmune, San Francisco, CA 94080, USA.

6. Department of Rheumatology and Clinical Immunology, Campus Kerchoff, Justus-Liebig University Giessen, 61231 Bad Nauheim, Germany.

Abstract

VIB4920, a nonantibody scaffold protein, blocks CD40L and reduces autoantibodies and disease activity in patients with rheumatoid arthritis.

Funder

AstraZeneca

MedImmune